Spots Global Cancer Trial Database for cancer of the thyroid
Every month we try and update this database with for cancer of the thyroid cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
---|---|---|---|---|---|---|
A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001) | NCT03157128 | Non-Small Cell ... Medullary Thyro... Colon Cancer Any Solid Tumor | LOXO-292 | 12 Years - | Eli Lilly and Company | |
Evaluation of Lancet Blood Sampling for Radioiodine Dosimetry in Thyroid Cancer | NCT02658513 | Cancer of the T... Cancer of Thyro... Thyroid Cancer Thyroid Carcino... | Lancet blood sa... Standard intrav... | 18 Years - | Royal Surrey County Hospital NHS Foundation Trust | |
A Study of Oral LOXO-292 (Selpercatinib) in Pediatric Participants With Advanced Solid or Primary Central Nervous System (CNS) Tumors | NCT03899792 | Medullary Thyro... Infantile Myofi... Infantile Fibro... Papillary Thyro... Soft Tissue Sar... | LOXO-292 | 6 Months - 21 Years | Eli Lilly and Company | |
A Study of Oral LOXO-292 (Selpercatinib) in Pediatric Participants With Advanced Solid or Primary Central Nervous System (CNS) Tumors | NCT03899792 | Medullary Thyro... Infantile Myofi... Infantile Fibro... Papillary Thyro... Soft Tissue Sar... | LOXO-292 | 6 Months - 21 Years | Eli Lilly and Company | |
A Study of Cabozantinib Compared With Placebo in Subjects With Radioiodine-refractory Differentiated Thyroid Cancer Who Have Progressed After Prior Vascular Endothelial Growth Factor Receptor (VEGFR) -Targeted Therapy | NCT03690388 | Differentiated ... | Cabozantinib Placebo | 16 Years - | Exelixis | |
Evaluation of Lancet Blood Sampling for Radioiodine Dosimetry in Thyroid Cancer | NCT02658513 | Cancer of the T... Cancer of Thyro... Thyroid Cancer Thyroid Carcino... | Lancet blood sa... Standard intrav... | 18 Years - | Royal Surrey County Hospital NHS Foundation Trust | |
Biomarkers to Distinguish Benign From Malignant Thyroid Neoplasm | NCT01433809 | Cancer of the T... Neoplasms, Thyr... Thyroid Adenoma Thyroid Cancer Thyroid Carcino... | 18 Years - 90 Years | Mayo Clinic |